VRTX241129C330000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals (NASDAQ:VRTX) Pulls Back 6.9% This Week, but Still Delivers Shareholders Strong 34% CAGR Over 3 Years
Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock
Vertex Trust Sells $3.79 Million in Shares
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560
Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $486
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Vertex Pharmaceuticals: Promising Growth With Suzetrigine Potential and Strategic Diversification
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $490
Vertex Pharmaceuticals (VRTX) Receives a Hold From Stifel Nicolaus
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Top 10 Most Expensive Stocks (Only 1 Gets a Quant Sell)
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
Shares of Pharmaceutical Companies Are Trading Lower After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS.
Vertex Pharmaceuticals Hits 5-week Low
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Orsini Now Distributing CASGEVY (Exagamglogene Autotemcel), a Gene-Editing Therapy